MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness.
Margherita PuppoManoj Kumar ValluruMartine CrosetDavide CeresaMichele IulianiAshrin KhanJulien WicinskiEmmanuelle Charafe-JauffretChristophe GinestierFrancesco PantanoPenelope Dawn OttewellPhilippe ClézardinPublished in: British journal of cancer (2023)
MiR-662 is involved in BC metastasis progression, suggesting it may be used as a prognostic marker to identify BC patients at high risk of metastasis.